New Antineoplastics Research from Arizona State University Outlined [An Isochroman Analog of CD3254 and Allyl-, Isochroman-Analogs of NEt-TMN Prove to Be More Potent Retinoid-X-Receptor (RXR) Selective Agonists Than Bexarotene]

Press/Media: Press / Media

PeriodJan 9 2023

Media coverage

1

Media coverage

  • TitleNew Antineoplastics Research from Arizona State University Outlined [An Isochroman Analog of CD3254 and Allyl-, Isochroman-Analogs of NEt-TMN Prove to Be More Potent Retinoid-X-Receptor (RXR) Selective Agonists Than Bexarotene]
    Media name/outletNewsRx Hematology Daily
    Country/TerritoryUnited States
    Date1/9/23
    PersonsPeter Jurutka, Pamela Marshall, Carl Wagner
View all 1
View less

Related content